Document is current
Any future updates will be listed below
-
Authors
Benlala, Ilyes https://orcid.org/0000-0002-5953-9882
Dournes, Gaël
Girodet, Pierre-Olivier
Laurent, François
Ben Hassen, Wadie
Baldacci, Fabien
De Senneville, Baudouin Denis
Berger, Patrick
-
Funding
Funding for this research was provided by:
European Society of Thoracic Imaging (Researcher Support Programme awarded by the European Society of Thoracic Imaging2022)
- License Information
-
More Information
Article History
Received: 28 October 2024
Accepted: 16 February 2025
First Online: 25 March 2025
Declarations
:
: The local ethics committee approved the study, and all participants were required to give written informed consent (ClinicalTrials.gov number: NCT03089346).
: The consent for publication of individual images in this manuscript was obtained.
: The authors of this manuscript declare relationships with the following companies: I. Benlala has a patent “Method for generating a biomarker system” (PCT/EP2020/065380) pending. G. Dournes has a patent “Method for geometrical characterization of the airways of the lung by MRI” (EP number 17726309.2) issued and a patent “Method for generating a biomarker system” (PCT/EP2020/065380) pending. P.-O. Girodet reports grants, personal fees and non-financial support from AstraZeneca, and personal fees and non-financial support from GSK, Novartis and Sanofi, outside the submitted work; and has a patent “New compositions and methods of treating and/or preventing COPD” (EP number 3050574, PCT/EP2016/051771) issued and a patent “New compositions and methods of treating COVID-19 disease” (EP number 20173595.8) pending. F. Laurent reports personal fees and non-financial support from Chiesi, Boehringer, AstraZeneca, Bayer, Gilead and GSK, outside the submitted work; and has a patent “Method for geometrical characterization of the airways of the lung by MRI” (EP number 17726309.2) issued and a patent “Method for generating a biomarker system” (PCT/EP2020/065380) pending. P. Berger reports grants from Novartis SAS, France, during the conduct of the study; grants, personal fees and non-financial support from AstraZeneca, GSK, Novartis, Chiesi and Boehringer, and personal fees and non-financial support from Menarini and Sanofi, outside the submitted work; and has a patent “New compositions and methods of treating and/or preventing COPD” (EP number 3050574, PCT/EP2016/051771) issued, a patent “Method for geometrical characterization of the airways of the lung by MRI” (EP number 17726309.2) issued, a patent “Method for generating a biomarker system” (PCT/EP2020/065380) pending and a patent “New compositions and methods of treating COVID-19 disease” (EP number 20173595.8) pending. One of the authors (Wadie Ben Hassen) is an employee of Siemens HealthCare.
